UA73134C2 - Use of drugs possessing protective activity against oxidative-toxic effects of medicaments or chemicals, in particular cardiotoxic drugs - Google Patents

Use of drugs possessing protective activity against oxidative-toxic effects of medicaments or chemicals, in particular cardiotoxic drugs Download PDF

Info

Publication number: UA73134C2
Authority: UA; Ukraine
Prior art keywords: group; formula; compounds; treatment; cardiotoxic
Prior art date: 1999-07-13

Application number

UA2002021058A

Other languages

English (en)

Ukrainian (uk)

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1999-07-13

Filing date

2000-10-07

Publication date

2005-06-15

2000-10-07 Application filed filed Critical

2005-06-15 Publication of UA73134C2 publication Critical patent/UA73134C2/uk

Links

230000000694 effects Effects 0.000 title claims abstract description 27
239000003814 drug Substances 0.000 title claims abstract description 26
230000001451 cardiotoxic effect Effects 0.000 title claims abstract description 21
231100000457 cardiotoxic Toxicity 0.000 title claims abstract description 19
229940079593 drug Drugs 0.000 title claims description 21
239000000126 substance Substances 0.000 title abstract description 10
230000001681 protective effect Effects 0.000 title 1
238000011282 treatment Methods 0.000 claims abstract description 38
150000003839 salts Chemical class 0.000 claims abstract description 22
239000000824 cytostatic agent Substances 0.000 claims abstract description 18
230000001085 cytostatic effect Effects 0.000 claims abstract description 14
241000124008 Mammalia Species 0.000 claims abstract description 12
238000002512 chemotherapy Methods 0.000 claims abstract description 7
238000009098 adjuvant therapy Methods 0.000 claims abstract description 4
150000001875 compounds Chemical class 0.000 claims description 78
125000000217 alkyl group Chemical group 0.000 claims description 25
RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 claims description 20
238000000034 method Methods 0.000 claims description 15
239000000203 mixture Substances 0.000 claims description 15
125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 15
QTBSBXVTEAMEQO-UHFFFAOYSA-N acetic acid Substances CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 claims description 13
239000003242 anti bacterial agent Substances 0.000 claims description 12
208000019622 heart disease Diseases 0.000 claims description 12
239000002253 acid Substances 0.000 claims description 11
125000004432 carbon atom Chemical group C* 0.000 claims description 11
230000002265 prevention Effects 0.000 claims description 11
-1 (2,2-dimethyl-1,3-dioxolan-4-yl)methyl Chemical group 0.000 claims description 10
239000008194 pharmaceutical composition Substances 0.000 claims description 8
229940045799 anthracyclines and related substance Drugs 0.000 claims description 7
229940088710 antibiotic agent Drugs 0.000 claims description 7
230000003115 biocidal effect Effects 0.000 claims description 7
238000002360 preparation method Methods 0.000 claims description 7
239000000651 prodrug Substances 0.000 claims description 7
229940002612 prodrug Drugs 0.000 claims description 7
230000001225 therapeutic effect Effects 0.000 claims description 7
239000000654 additive Substances 0.000 claims description 6
229910052739 hydrogen Inorganic materials 0.000 claims description 6
239000001257 hydrogen Substances 0.000 claims description 6
MWWSFMDVAYGXBV-MYPASOLCSA-N (7r,9s)-7-[(2r,4s,5s,6s)-4-amino-5-hydroxy-6-methyloxan-2-yl]oxy-6,9,11-trihydroxy-9-(2-hydroxyacetyl)-4-methoxy-8,10-dihydro-7h-tetracene-5,12-dione;hydrochloride Chemical compound Cl.O([C@@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 MWWSFMDVAYGXBV-MYPASOLCSA-N 0.000 claims description 5
208000020446 Cardiac disease Diseases 0.000 claims description 5
208000031229 Cardiomyopathies Diseases 0.000 claims description 5
UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 5
239000002552 dosage form Substances 0.000 claims description 5
125000002947 alkylene group Chemical group 0.000 claims description 4
231100000433 cytotoxic Toxicity 0.000 claims description 4
230000001472 cytotoxic effect Effects 0.000 claims description 4
229910052736 halogen Inorganic materials 0.000 claims description 4
150000002367 halogens Chemical class 0.000 claims description 4
AOJJSUZBOXZQNB-VTZDEGQISA-N 4'-epidoxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-VTZDEGQISA-N 0.000 claims description 3
STQGQHZAVUOBTE-UHFFFAOYSA-N 7-Cyan-hept-2t-en-4,6-diinsaeure Natural products C1=2C(O)=C3C(=O)C=4C(OC)=CC=CC=4C(=O)C3=C(O)C=2CC(O)(C(C)=O)CC1OC1CC(N)C(O)C(C)O1 STQGQHZAVUOBTE-UHFFFAOYSA-N 0.000 claims description 3
HTIJFSOGRVMCQR-UHFFFAOYSA-N Epirubicin Natural products COc1cccc2C(=O)c3c(O)c4CC(O)(CC(OC5CC(N)C(=O)C(C)O5)c4c(O)c3C(=O)c12)C(=O)CO HTIJFSOGRVMCQR-UHFFFAOYSA-N 0.000 claims description 3
230000000996 additive effect Effects 0.000 claims description 3
229960000975 daunorubicin Drugs 0.000 claims description 3
STQGQHZAVUOBTE-VGBVRHCVSA-N daunorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(C)=O)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 STQGQHZAVUOBTE-VGBVRHCVSA-N 0.000 claims description 3
229960001904 epirubicin Drugs 0.000 claims description 3
229960001156 mitoxantrone Drugs 0.000 claims description 3
KKZJGLLVHKMTCM-UHFFFAOYSA-N mitoxantrone Chemical compound O=C1C2=C(O)C=CC(O)=C2C(=O)C2=C1C(NCCNCCO)=CC=C2NCCNCCO KKZJGLLVHKMTCM-UHFFFAOYSA-N 0.000 claims description 3
239000000546 pharmaceutical excipient Substances 0.000 claims description 3
229940124531 pharmaceutical excipient Drugs 0.000 claims description 3
WNXJIVFYUVYPPR-UHFFFAOYSA-N 1,3-dioxolane Chemical group C1COCO1 WNXJIVFYUVYPPR-UHFFFAOYSA-N 0.000 claims description 2
208000021908 Myocardial disease Diseases 0.000 claims description 2
125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims description 2
230000003293 cardioprotective effect Effects 0.000 claims description 2
230000001120 cytoprotective effect Effects 0.000 claims description 2
125000003392 indanyl group Chemical group C1(CCC2=CC=CC=C12)* 0.000 claims description 2
125000001624 naphthyl group Chemical group 0.000 claims description 2
206010019280 Heart failures Diseases 0.000 claims 1
238000012876 topography Methods 0.000 claims 1
238000002560 therapeutic procedure Methods 0.000 abstract description 5
229910052757 nitrogen Inorganic materials 0.000 abstract description 4
125000004433 nitrogen atom Chemical group N* 0.000 abstract description 4
NTQSYIWTDXTRGG-UHFFFAOYSA-N 2-(1-benzazepin-1-yl)acetic acid Chemical class OC(=O)CN1C=CC=CC2=CC=CC=C12 NTQSYIWTDXTRGG-UHFFFAOYSA-N 0.000 abstract description 3
230000003683 cardiac damage Effects 0.000 abstract description 3
125000004043 oxo group Chemical group O=* 0.000 abstract description 3
150000002148 esters Chemical class 0.000 abstract description 2
238000011321 prophylaxis Methods 0.000 abstract 3
241000282414 Homo sapiens Species 0.000 abstract 1
230000003680 myocardial damage Effects 0.000 abstract 1
AOJJSUZBOXZQNB-TZSSRYMLSA-N Doxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 description 80
229940009456 adriamycin Drugs 0.000 description 40
241001465754 Metazoa Species 0.000 description 36
239000000902 placebo Substances 0.000 description 12
229940068196 placebo Drugs 0.000 description 12
230000037396 body weight Effects 0.000 description 7
238000002474 experimental method Methods 0.000 description 7
229940126601 medicinal product Drugs 0.000 description 7
238000012360 testing method Methods 0.000 description 7
PMMYEEVYMWASQN-DMTCNVIQSA-N Hydroxyproline Chemical compound O[C@H]1CN[C@H](C(O)=O)C1 PMMYEEVYMWASQN-DMTCNVIQSA-N 0.000 description 6
241000700159 Rattus Species 0.000 description 6
230000003078 antioxidant effect Effects 0.000 description 6
PMMYEEVYMWASQN-UHFFFAOYSA-N dl-hydroxyproline Natural products OC1C[NH2+]C(C([O-])=O)C1 PMMYEEVYMWASQN-UHFFFAOYSA-N 0.000 description 6
229960002591 hydroxyproline Drugs 0.000 description 6
239000000243 solution Substances 0.000 description 6
FGMPLJWBKKVCDB-UHFFFAOYSA-N trans-L-hydroxy-proline Natural products ON1CCCC1C(O)=O FGMPLJWBKKVCDB-UHFFFAOYSA-N 0.000 description 6
GVJHHUAWPYXKBD-IEOSBIPESA-N α-tocopherol Chemical compound OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-IEOSBIPESA-N 0.000 description 6
102100023321 Ceruloplasmin Human genes 0.000 description 5
108010075016 Ceruloplasmin Proteins 0.000 description 5
206010048610 Cardiotoxicity Diseases 0.000 description 4
241000283973 Oryctolagus cuniculus Species 0.000 description 4
239000013543 active substance Substances 0.000 description 4
231100000259 cardiotoxicity Toxicity 0.000 description 4
238000000354 decomposition reaction Methods 0.000 description 4
150000001991 dicarboxylic acids Chemical class 0.000 description 4
230000002829 reductive effect Effects 0.000 description 4
238000007634 remodeling Methods 0.000 description 4
125000001424 substituent group Chemical group 0.000 description 4
239000003826 tablet Substances 0.000 description 4
229920002261 Corn starch Polymers 0.000 description 3
GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 3
239000008120 corn starch Substances 0.000 description 3
AQEFLFZSWDEAIP-UHFFFAOYSA-N di-tert-butyl ether Chemical compound CC(C)(C)OC(C)(C)C AQEFLFZSWDEAIP-UHFFFAOYSA-N 0.000 description 3
150000002170 ethers Chemical class 0.000 description 3
239000008101 lactose Substances 0.000 description 3
230000001590 oxidative effect Effects 0.000 description 3
GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 2
ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 2
PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 description 2
WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 2
108010010803 Gelatin Proteins 0.000 description 2
206010028594 Myocardial fibrosis Diseases 0.000 description 2
150000007513 acids Chemical class 0.000 description 2
229940087168 alpha tocopherol Drugs 0.000 description 2
150000001408 amides Chemical group 0.000 description 2
201000011510 cancer Diseases 0.000 description 2
229910052799 carbon Inorganic materials 0.000 description 2
229910052801 chlorine Inorganic materials 0.000 description 2
239000000460 chlorine Substances 0.000 description 2
230000002354 daily effect Effects 0.000 description 2
MHDVGSVTJDSBDK-UHFFFAOYSA-N dibenzyl ether Chemical compound C=1C=CC=CC=1COCC1=CC=CC=C1 MHDVGSVTJDSBDK-UHFFFAOYSA-N 0.000 description 2
229910052731 fluorine Inorganic materials 0.000 description 2
239000011737 fluorine Substances 0.000 description 2
229920000159 gelatin Polymers 0.000 description 2
239000008273 gelatin Substances 0.000 description 2
235000019322 gelatine Nutrition 0.000 description 2
235000011852 gelatine desserts Nutrition 0.000 description 2
239000008187 granular material Substances 0.000 description 2
210000005003 heart tissue Anatomy 0.000 description 2
238000002347 injection Methods 0.000 description 2
239000007924 injection Substances 0.000 description 2
238000001990 intravenous administration Methods 0.000 description 2
239000007788 liquid Substances 0.000 description 2
HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
239000012528 membrane Substances 0.000 description 2
WEXRUCMBJFQVBZ-UHFFFAOYSA-N pentobarbital Chemical compound CCCC(C)C1(CC)C(=O)NC(=O)NC1=O WEXRUCMBJFQVBZ-UHFFFAOYSA-N 0.000 description 2
230000003244 pro-oxidative effect Effects 0.000 description 2
239000007787 solid Substances 0.000 description 2
239000000454 talc Substances 0.000 description 2
229910052623 talc Inorganic materials 0.000 description 2
229960000984 tocofersolan Drugs 0.000 description 2
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
239000002076 α-tocopherol Substances 0.000 description 2
235000004835 α-tocopherol Nutrition 0.000 description 2
ZCXLTWVZYXBHJS-UHFFFAOYSA-N 1,2-benzoxazepine Chemical compound O1N=CC=CC2=CC=CC=C12 ZCXLTWVZYXBHJS-UHFFFAOYSA-N 0.000 description 1
DQFQCHIDRBIESA-UHFFFAOYSA-N 1-benzazepine Chemical compound N1C=CC=CC2=CC=CC=C12 DQFQCHIDRBIESA-UHFFFAOYSA-N 0.000 description 1
ZRVKEVKIXFZQMC-UHFFFAOYSA-N 2-(azepin-1-yl)acetic acid Chemical compound OC(=O)CN1C=CC=CC=C1 ZRVKEVKIXFZQMC-UHFFFAOYSA-N 0.000 description 1
125000000094 2-phenylethyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])C([H])([H])* 0.000 description 1
208000035143 Bacterial infection Diseases 0.000 description 1
WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 1
206010007572 Cardiac hypertrophy Diseases 0.000 description 1
206010020880 Hypertrophy Diseases 0.000 description 1
DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
229920002472 Starch Polymers 0.000 description 1
229930003427 Vitamin E Natural products 0.000 description 1
125000004423 acyloxy group Chemical group 0.000 description 1
125000005042 acyloxymethyl group Chemical group 0.000 description 1
229910052783 alkali metal Inorganic materials 0.000 description 1
150000001340 alkali metals Chemical class 0.000 description 1
229910052784 alkaline earth metal Inorganic materials 0.000 description 1
150000001342 alkaline earth metals Chemical class 0.000 description 1
125000003545 alkoxy group Chemical group 0.000 description 1
150000001412 amines Chemical class 0.000 description 1
150000001413 amino acids Chemical class 0.000 description 1
150000003863 ammonium salts Chemical class 0.000 description 1
238000010171 animal model Methods 0.000 description 1
208000022362 bacterial infectious disease Diseases 0.000 description 1
230000009286 beneficial effect Effects 0.000 description 1
230000015572 biosynthetic process Effects 0.000 description 1
239000008280 blood Substances 0.000 description 1
210000004369 blood Anatomy 0.000 description 1
GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 1
229910052794 bromium Inorganic materials 0.000 description 1
159000000007 calcium salts Chemical class 0.000 description 1
239000002775 capsule Substances 0.000 description 1
230000000747 cardiac effect Effects 0.000 description 1
230000009787 cardiac fibrosis Effects 0.000 description 1
239000000969 carrier Substances 0.000 description 1
230000001364 causal effect Effects 0.000 description 1
210000000170 cell membrane Anatomy 0.000 description 1
239000003795 chemical substances by application Substances 0.000 description 1
150000005690 diesters Chemical class 0.000 description 1
HPNMFZURTQLUMO-UHFFFAOYSA-N diethylamine Chemical compound CCNCC HPNMFZURTQLUMO-UHFFFAOYSA-N 0.000 description 1
230000003203 everyday effect Effects 0.000 description 1
230000002349 favourable effect Effects 0.000 description 1
230000004761 fibrosis Effects 0.000 description 1
238000009472 formulation Methods 0.000 description 1
WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 description 1
125000004435 hydrogen atom Chemical group [H]* 0.000 description 1
230000002401 inhibitory effect Effects 0.000 description 1
230000005764 inhibitory process Effects 0.000 description 1
229910052740 iodine Inorganic materials 0.000 description 1
230000002427 irreversible effect Effects 0.000 description 1
210000005240 left ventricle Anatomy 0.000 description 1
150000002632 lipids Chemical class 0.000 description 1
235000019359 magnesium stearate Nutrition 0.000 description 1
239000011159 matrix material Substances 0.000 description 1
125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 description 1
125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
230000002107 myocardial effect Effects 0.000 description 1
210000004165 myocardium Anatomy 0.000 description 1
125000004998 naphthylethyl group Chemical group C1(=CC=CC2=CC=CC=C12)CC* 0.000 description 1
230000007935 neutral effect Effects 0.000 description 1
230000003647 oxidation Effects 0.000 description 1
238000007254 oxidation reaction Methods 0.000 description 1
230000004792 oxidative damage Effects 0.000 description 1
229960001412 pentobarbital Drugs 0.000 description 1
230000035699 permeability Effects 0.000 description 1
230000000144 pharmacologic effect Effects 0.000 description 1
239000003755 preservative agent Substances 0.000 description 1
230000003449 preventive effect Effects 0.000 description 1
230000000069 prophylactic effect Effects 0.000 description 1
239000008213 purified water Substances 0.000 description 1
238000011160 research Methods 0.000 description 1
229910052708 sodium Inorganic materials 0.000 description 1
239000011734 sodium Substances 0.000 description 1
239000002904 solvent Substances 0.000 description 1
241000894007 species Species 0.000 description 1
239000008107 starch Substances 0.000 description 1
235000019698 starch Nutrition 0.000 description 1
239000000829 suppository Substances 0.000 description 1
239000007885 tablet disintegrant Substances 0.000 description 1
YBRBMKDOPFTVDT-UHFFFAOYSA-N tert-butylamine Chemical compound CC(C)(C)N YBRBMKDOPFTVDT-UHFFFAOYSA-N 0.000 description 1
229940124597 therapeutic agent Drugs 0.000 description 1
210000001519 tissue Anatomy 0.000 description 1
239000011732 tocopherol Substances 0.000 description 1
229960001295 tocopherol Drugs 0.000 description 1
231100000331 toxic Toxicity 0.000 description 1
230000002588 toxic effect Effects 0.000 description 1
229940088594 vitamin Drugs 0.000 description 1
239000011782 vitamin Substances 0.000 description 1
229930003231 vitamin Natural products 0.000 description 1
235000013343 vitamin Nutrition 0.000 description 1
239000011709 vitamin E Substances 0.000 description 1
235000019165 vitamin E Nutrition 0.000 description 1
229940046009 vitamin E Drugs 0.000 description 1
150000003722 vitamin derivatives Chemical class 0.000 description 1
238000005303 weighing Methods 0.000 description 1
229960000641 zorubicin Drugs 0.000 description 1
FBTUMDXHSRTGRV-ALTNURHMSA-N zorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(\C)=N\NC(=O)C=1C=CC=CC=1)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 FBTUMDXHSRTGRV-ALTNURHMSA-N 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
- A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
- A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A61P39/02—Antidotes
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A61P39/06—Free radical scavengers or antioxidants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Animal Behavior & Ethology (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Organic Chemistry (AREA)
Epidemiology (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Cardiology (AREA)
Immunology (AREA)
Heart & Thoracic Surgery (AREA)
Toxicology (AREA)
Molecular Biology (AREA)
Hospice & Palliative Care (AREA)
Orthopedic Medicine & Surgery (AREA)
Physical Education & Sports Medicine (AREA)
Neurology (AREA)
Biochemistry (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

UA2002021058A 1999-07-13 2000-10-07 Use of drugs possessing protective activity against oxidative-toxic effects of medicaments or chemicals, in particular cardiotoxic drugs UA73134C2 (en)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
DE19932555A DE19932555A1 (de)	1999-07-13	1999-07-13	Arzneimittel mit protektiver Wirkung gegen oxidativ-toxische und insbesondere gegen kardiotoxische Substanzen
PCT/EP2000/006525 WO2001003699A1 (de)	1999-07-13	2000-07-10	Arzneimittel mit protektiver wirkung gegen oxidativ-toxische und insbesondere gegen kardiotoxische substanzen

Publications (1)

Publication Number	Publication Date
UA73134C2 true UA73134C2 (en)	2005-06-15

Family

ID=7914519

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
UA2002021058A UA73134C2 (en)	1999-07-13	2000-10-07	Use of drugs possessing protective activity against oxidative-toxic effects of medicaments or chemicals, in particular cardiotoxic drugs

Country Status (28)

Country	Link
US (1)	US6906059B2 (cs)
EP (1)	EP1200095B1 (cs)
JP (1)	JP4824235B2 (cs)
KR (1)	KR100738940B1 (cs)
CN (1)	CN1267099C (cs)
AR (1)	AR024476A1 (cs)
AT (1)	ATE306926T1 (cs)
AU (1)	AU782733B2 (cs)
BR (1)	BR0012442A (cs)
CA (1)	CA2377904C (cs)
CZ (1)	CZ299070B6 (cs)
DE (2)	DE19932555A1 (cs)
DK (1)	DK1200095T3 (cs)
ES (1)	ES2246874T3 (cs)
HK (1)	HK1049116B (cs)
HU (1)	HUP0202424A3 (cs)
IL (2)	IL147604A0 (cs)
MX (1)	MXPA02000411A (cs)
NO (1)	NO329558B1 (cs)
NZ (1)	NZ517130A (cs)
PL (1)	PL198723B1 (cs)
RU (1)	RU2268727C2 (cs)
SK (1)	SK286020B6 (cs)
TR (1)	TR200200053T2 (cs)
TW (1)	TWI280880B (cs)
UA (1)	UA73134C2 (cs)
WO (1)	WO2001003699A1 (cs)
ZA (1)	ZA200200265B (cs)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
DE19932555A1 (de) *	1999-07-13	2001-01-18	Solvay Pharm Gmbh	Arzneimittel mit protektiver Wirkung gegen oxidativ-toxische und insbesondere gegen kardiotoxische Substanzen
SK14102003A3 (sk) *	2001-05-18	2004-08-03	Solvay Pharmaceuticals Gmbh	Použitie zlúčenín s kombinovanou inhibičnou aktivitou k NEP/MP pri príprave liečiv
ES2338538T3 (es) *	2001-09-10	2010-05-10	Tibotec Pharmaceuticals	Metodo para la preparacion de hexahidrofuro(2,3-b)furan-3-ol.
BR0306701A (pt) *	2002-01-16	2004-12-28	Solvay Pharm Bv	Composto, sal do composto, sal de cálcio, método de preparação de um sal, composição farmacêutica, método de preparação de uma composição, e, uso de um sal
AR038681A1 (es) *	2002-02-14	2005-01-26	Solvay Pharm Bv	Formulacion oral de solucion solida de una sustancia activa pobremente soluble en agua
US7452875B2 (en)	2003-09-26	2008-11-18	Solvay Pharmaceuticals Gmbh	Amidomethyl-substituted 1-(carboxyalkyl) cyclopentyl-carbonylamino-benzazepine-N-acetic acid compounds, process and intermediate products for their preparation and pharmaceutical compositions containing them
US7427611B2 (en)	2003-09-26	2008-09-23	Solvay Pharmaceuticals Gmbh	Amidomethyl-substituted 1-(carboxyalkyl)-cyclopentyl-carbonylamino-benzazepine-N-acetic acid compounds, process and intermediate products for their preparation and pharmaceutical compositions containing them
US7262184B2 (en)	2003-09-26	2007-08-28	Solvay Pharmaceuticals Gmbh	Amidomethyl-substituted 1-(carboxyalkyl) cyclopentyl-carbonylamino-benzazepine-N-acetic acid compounds, process and intermediate products for their preparation and pharmaceutical compositions containing them
AR046454A1 (es) *	2003-11-18	2005-12-07	Solvay Pharm Gmbh	Uso de un compuesto de acido benzazepin-n-acetico, composicion farmaceutica, y procedimiento para la produccion de dicha composicion farmaceutica
US20050267072A1 (en) *	2004-05-14	2005-12-01	Solvay Pharmaceuticals Gmbh	Pharmaceutical compositions containing dually acting inhibitors of neutral endopeptidase for the treatment of sexual dysfunction
US20050267124A1 (en) *	2004-05-14	2005-12-01	Solvay Pharmaceuticals Gmbh	Pharmaceutical compositions comprising NEP-inhibitors, inhibitors of the endogenous producing system and PDEV inhibiitors
US20050288272A1 (en) *	2004-06-23	2005-12-29	Solvay Pharmaceuticals Gmbh	Pharmaceutical compositions comprising NEP-inhibitors, inhibitors of the endogenous endothelin producing system and AT1 receptor antagonists
WO2006064016A1 (en)	2004-12-15	2006-06-22	Solvay Pharmaceuticals Gmbh	Pharmaceutical compositions comprising nep-inhibitors, inhibitors of the endogenous endothelin producing system and hmg coa reductase inhibitors
US20060205625A1 (en) *	2005-02-18	2006-09-14	Solvay Pharmaceuticals Gmbh	Pharmaceutical compositions comprising NEP-inhibitors, inhibitors of the endogenous endothelin producing system and diuretics
US8709738B2 (en) *	2006-02-27	2014-04-29	Quintiles Transnational Corporation	Methods for predicting cardiac toxicity
WO2007102171A2 (en) *	2006-03-07	2007-09-13	Panacea Biotec Ltd	Novel salts of 1h-1-benzazepine-1-acetic acid, their preparation and pharmaceutical composition
US20070292503A1 (en) *	2006-06-16	2007-12-20	Gorissen Henricus R	Oral pharmaceutical composition of poorly water-soluble active substance
US20070299054A1 (en) *	2006-06-22	2007-12-27	Rajesh Jain	Oral pharmaceutical composition of a poorly water-soluble active agent

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
DE2850078A1 (de) *	1978-11-18	1980-05-29	Basf Ag	Aminopropanolderivate des 6-hydroxy-2,3,4,5-tetrahydro-1h-1- benzazepin-2-ons
CN1040210C (zh) *	1993-07-21	1998-10-14	山之内制药株式会社	稠合的苯并氮杂䓬衍生物及其药学组合物
DE19510566A1 (de) *	1995-03-23	1996-09-26	Kali Chemie Pharma Gmbh	Benzazepin-, Benzoxazepin- und Benzothiazepin-N-essigsäurederivate sowie Verfahren zu ihrer Herstellung und diese Verbindungen enthaltende Arzneimittel
DE19638020A1 (de) *	1996-09-18	1998-03-19	Solvay Pharm Gmbh	Die gastrointestinale Durchblutung fördernde Arzneimittel
AU1146099A (en) *	1997-09-18	1999-04-05	Janssen Pharmaceutica N.V.	Fused imidazole derivatives for improving oral bioavailability of pharmaceuticalagents
DE19906310A1 (de) *	1999-02-16	2000-08-17	Solvay Pharm Gmbh	Arzneimittel zur Behandlung von Bluthochdruck
DE19932555A1 (de) *	1999-07-13	2001-01-18	Solvay Pharm Gmbh	Arzneimittel mit protektiver Wirkung gegen oxidativ-toxische und insbesondere gegen kardiotoxische Substanzen

1999
- 1999-07-13 DE DE19932555A patent/DE19932555A1/de not_active Withdrawn
2000
- 2000-06-23 AR ARP000103183A patent/AR024476A1/es unknown
- 2000-07-05 TW TW089113263A patent/TWI280880B/zh active
- 2000-07-10 ES ES00947960T patent/ES2246874T3/es not_active Expired - Lifetime
- 2000-07-10 RU RU2002102709/15A patent/RU2268727C2/ru not_active IP Right Cessation
- 2000-07-10 SK SK14-2002A patent/SK286020B6/sk not_active IP Right Cessation
- 2000-07-10 EP EP00947960A patent/EP1200095B1/de not_active Expired - Lifetime
- 2000-07-10 JP JP2001508979A patent/JP4824235B2/ja not_active Expired - Fee Related
- 2000-07-10 AT AT00947960T patent/ATE306926T1/de active
- 2000-07-10 DE DE50011388T patent/DE50011388D1/de not_active Expired - Lifetime
- 2000-07-10 PL PL353012A patent/PL198723B1/pl not_active IP Right Cessation
- 2000-07-10 CZ CZ20020052A patent/CZ299070B6/cs not_active IP Right Cessation
- 2000-07-10 KR KR1020027000361A patent/KR100738940B1/ko not_active Expired - Fee Related
- 2000-07-10 CA CA002377904A patent/CA2377904C/en not_active Expired - Fee Related
- 2000-07-10 MX MXPA02000411A patent/MXPA02000411A/es active IP Right Grant
- 2000-07-10 HU HU0202424A patent/HUP0202424A3/hu not_active Application Discontinuation
- 2000-07-10 TR TR2002/00053T patent/TR200200053T2/xx unknown
- 2000-07-10 BR BR0012442-7A patent/BR0012442A/pt not_active Application Discontinuation
- 2000-07-10 AU AU61572/00A patent/AU782733B2/en not_active Ceased
- 2000-07-10 IL IL14760400A patent/IL147604A0/xx active IP Right Grant
- 2000-07-10 DK DK00947960T patent/DK1200095T3/da active
- 2000-07-10 WO PCT/EP2000/006525 patent/WO2001003699A1/de not_active Ceased
- 2000-07-10 NZ NZ517130A patent/NZ517130A/en not_active IP Right Cessation
- 2000-07-10 HK HK03101159.2A patent/HK1049116B/zh not_active IP Right Cessation
- 2000-07-10 CN CNB008102015A patent/CN1267099C/zh not_active Expired - Fee Related
- 2000-10-07 UA UA2002021058A patent/UA73134C2/uk unknown
2002
- 2002-01-11 ZA ZA200200265A patent/ZA200200265B/xx unknown
- 2002-01-11 NO NO20020132A patent/NO329558B1/no not_active IP Right Cessation
- 2002-01-13 IL IL147604A patent/IL147604A/en not_active IP Right Cessation
- 2002-01-14 US US10/043,268 patent/US6906059B2/en not_active Expired - Fee Related

Also Published As

Publication number	Publication date
AU6157200A (en)	2001-01-30
IL147604A (en)	2006-12-31
BR0012442A (pt)	2002-04-02
ZA200200265B (en)	2003-03-26
CZ200252A3 (cs)	2002-08-14
HUP0202424A3 (en)	2003-03-28
PL198723B1 (pl)	2008-07-31
CA2377904C (en)	2009-03-24
NO20020132D0 (no)	2002-01-11
EP1200095A1 (de)	2002-05-02
HK1049116A1 (en)	2003-05-02
KR20020019514A (ko)	2002-03-12
CN1373666A (zh)	2002-10-09
SK286020B6 (sk)	2008-01-07
NZ517130A (en)	2004-10-29
DE19932555A1 (de)	2001-01-18
CZ299070B6 (cs)	2008-04-16
NO329558B1 (no)	2010-11-15
WO2001003699A1 (de)	2001-01-18
IL147604A0 (en)	2002-08-14
RU2268727C2 (ru)	2006-01-27
TWI280880B (en)	2007-05-11
AR024476A1 (es)	2002-10-02
NO20020132L (no)	2002-03-12
SK142002A3 (en)	2002-06-04
ATE306926T1 (de)	2005-11-15
KR100738940B1 (ko)	2007-07-12
DK1200095T3 (da)	2005-11-14
PL353012A1 (en)	2003-10-06
CA2377904A1 (en)	2001-01-18
TR200200053T2 (tr)	2002-05-21
CN1267099C (zh)	2006-08-02
US6906059B2 (en)	2005-06-14
ES2246874T3 (es)	2006-03-01
DE50011388D1 (de)	2006-03-02
US20030040512A1 (en)	2003-02-27
MXPA02000411A (es)	2002-07-02
JP4824235B2 (ja)	2011-11-30
HUP0202424A2 (hu)	2002-11-28
HK1049116B (zh)	2006-12-08
JP2003504336A (ja)	2003-02-04
EP1200095B1 (de)	2005-10-19
AU782733B2 (en)	2005-08-25

Publication	Publication Date	Title
RU2268727C2 (ru)	2006-01-27	Лекарственное средство, обладающее защитным действием в отношении окислительно-токсических и прежде всего кардиотоксических соединений
AU2005311709B2 (en)	2011-07-28	Compositions and methods for treating neoplastic diseases
IE58335B1 (en)	1993-09-08	Pharmaceutical products providing enhanced analgesia
CZ290691B6 (cs)	2002-09-11	Farmaceutický prostředek
EP2263694A1 (en)	2010-12-22	Antitumor agent comprising the histone deacetylase inhibitor FK228 and a topoisomerase II inhibitor
EP1323423A1 (en)	2003-07-02	Combined preparations comprising anthracycline derivatives
RU2002102709A (ru)	2003-11-20	Лекарственное средство, обладающее защитным действием в отношении окислительно-токсических и прежде всего кардиотоксических соединений
KR20250167640A (ko)	2025-12-01	아즈부딘 및 화학요법제를 포함한 항종양 약학적 조성물
US20020115677A1 (en)	2002-08-22	Combination comprising camptothecin and a stilbene derivative for the treatment of cancer
KR20020016850A (ko)	2002-03-06	설사 예방 및 치료용 의약조성물
CZ310695A3 (en)	1996-04-17	The use of at least one acetal of podophyllotixin-{beta}-d-glucopyranoside or 4-demethylpodophyllotoxin-{beta}-d-glucopyranoside for preparing pharmaceutical compositions or prophylaxis of amyloidose states
EP0874630B1 (en)	2003-08-20	Topoisomerase ii poison and bis-dioxypiperazine derivative combination therapy
AU769533B2 (en)	2004-01-29	Treatment of accidental extravasation of anthracyclines
HK40061085A (en)	2022-05-27	Novel therapeutic method and novel therapeutic agent for hematological cancer
CA2741276A1 (en)	2010-05-20	Combined use of bendamustine, doxorubicin and bortezomib for the treatment of multiple myeloma
CN113727719A (zh)	2021-11-30	血癌的新型治疗方法及新型治疗剂
JPH07501521A (ja)	1995-02-16	２−アミノプロパン１，３−ジオール化学療法剤
KR20010080379A (ko)	2001-08-22	세포소멸을 유발시킬 수 있는 약제의 제조를 위한프로피오닐 ｌ-카르니틴의 용도